An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

This study is testing a medicine called inebilizumab in children and teenagers with Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD is a rare condition where the immune system attacks the nerves in the eyes and spine, and this trial aims to see if the drug is safe and effective at helping to prevent future symptom flare-ups.

This study is for children and teens between 2 and 17 years old who weigh at least 33 pounds and have been officially diagnosed with AQP4-IgG positive NMOSD. Participants must have experienced recent symptom flares to be eligible, and the study team will check your overall health and medical history to make sure it is safe for you to join.

If you join, you will receive the study medication, which works by targeting specific immune cells to lower inflammation. The researchers will monitor you closely through regular check-ups to track your progress, safety, and how your body reacts to the treatment.

This study is currently recruiting new participants. Research locations include specialized medical centers in La Jolla and Loma Linda, California, as well as Boston, Massachusetts.